

## FUTURE PLANS AND USE OF [REDACTED]

### FUTURE PLANS AND PROSPECTS

See “Business — Our Strategies” for a description of our future plans.

### USE OF [REDACTED]

We estimate that we will receive net [REDACTED] from the [REDACTED] of approximately [REDACTED], based on an [REDACTED] of [REDACTED] per [REDACTED] (being the mid-point of the indicative [REDACTED] range) and assuming no exercise of the [REDACTED], or [REDACTED] if the [REDACTED] is exercised in full, after deducting [REDACTED] fees and [REDACTED] and other estimated [REDACTED] paid and payable by us in relation to the [REDACTED].

In line with our strategies, we plan to use the net [REDACTED] from the [REDACTED] for the purposes and in the amounts set forth below:

- **[REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the continuing clinical research and development activities of our Core Products FT-002 and FT-003. In particular,**
  - o [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the continuing research and development of FT-002 in ongoing Phase II and future Phase III clinical trials for XLRP in China. See “Business — Our Drug Candidates — FT-002 — Material Communications and Next Steps”; and
  - o [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the continuing research and development of FT-003 in ongoing Phase II and future Phase III clinical trials for nAMD, DME and DR in China. See “Business — Our Drug Candidates — FT-003 — Material Communications and Next Steps.” In particular,
    - (1) [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be allocated for nAMD, including trial costs and research and development personnel expenses for the ongoing Phase II clinical trial, which was initiated in October 2024, and for future Phase III clinical trials in China;
    - (2) [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be allocated for DME, including trial costs and research and development personnel expenses for the ongoing Phase II clinical trial, which was initiated in November 2024, and for future Phase III clinical trials in China; and
    - (3) [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be allocated for DR, including trial costs and research and development personnel expenses for future Phase II/III clinical trials in China.

## FUTURE PLANS AND USE OF [REDACTED]

- [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund preparations for the commercial roll-out of our drug candidates in China, including registrational filings as well as establishing sales and marketing capabilities.
- [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the research and development of early-stage pipeline programs and cover other research and development related costs. In particular,
  - o [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the preclinical studies and future Phase I/II clinical trial costs for FT-023 for the treatment of nAMD, DME and DR in China;
  - o [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to fund the IND preparation and filing cost, other preclinical study costs, and the future Phase I clinical trial costs for FT-017 for the treatment of HCM in China; and
  - o [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used to advance other early-stage pipeline programs and cover other research and development related costs in China and the United States.
- [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used for investing in our manufactory capabilities in preparation for the market approval and commercialization of our drug candidates, including any facility upgrades that may be required in the future.
- [REDACTED] of the net [REDACTED], or approximately [REDACTED], will be used for working capital and other general corporate purposes.

In the event that the [REDACTED] is fixed at the high or low end of the indicative [REDACTED] range, the net [REDACTED] of the [REDACTED] will increase or decrease by approximately [REDACTED].

The additional net [REDACTED] that we would receive if the [REDACTED] were exercised in full would be (i) [REDACTED] (assuming an [REDACTED] of [REDACTED] per [REDACTED], being the high end of the [REDACTED] range), (ii) [REDACTED] (assuming an [REDACTED] of [REDACTED] per [REDACTED], being the mid-point of the [REDACTED] range) and (iii) [REDACTED] (assuming an [REDACTED] of [REDACTED] per [REDACTED], being the low end of the [REDACTED] range).

To the extent that the net [REDACTED] from the [REDACTED] (including the net [REDACTED] from the exercise of the [REDACTED]) are either more or less than expected, we may adjust our allocation of the net [REDACTED] for the above purposes on a pro rata basis.

**FUTURE PLANS AND USE OF [REDACTED]**

To the extent that the net [REDACTED] of the [REDACTED] are not immediately required for the above purposes or if we are unable to put into effect any part of our development plan as intended, we may hold such funds in bank deposits at authorized financial institutions and licensed banks. In such event, we will comply with the appropriate disclosure requirements under the Listing Rules.